A Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

About this Study

The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes.

Sponsor Protocol ID:E4512
IRB Number:2015-0239
Actively Enrolling
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion CriteriaNone

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:John Ruckdeschel
How to participate in our Clinical Trials